Immutep, Merck KGgA, Pfizer partner for Phase I immunotherapy combo trial

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP), Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) partnered to test Immutep's eftilagimod alpha (IMP321) in combination with the pharmas' anti-PD-L1 mAb Bavencio avelumab in a Phase I trial for patients with advanced solid tumors. Eftilagimod is a soluble recombinant fusion protein consisting of an Fc portion of a human Ig and a dimeric protein with four extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223).

The combination will be added to the existing Phase I INSIGHT trial sponsored by the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH (Frankfurt, Germany). ...